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ABSTRACT
Ovarian cancer is often termed a silent killer due to the late onset of symptoms. 
Whilst patients initially respond to chemotherapy, they rapidly develop chemo-
resistance. Oncolytic adenoviruses (OAds) are promising anti-cancer agents 
engineered to “hijack” the unique molecular machinery of cancer cells enabling 
tumour-selective viral replication. This allows spread to adjacent cells and 
amplification of oncolysis within the tumour. OAds represent an excellent opportunity 
for ovarian cancer therapy via intra-peritoneal delivery, however the efficacy of OAds 
thus far is limited. Here, we evaluate chromatin (histone) modification in chemo-
resistant cells and its relationship to Ad efficacy (wild-type or oncolytic Ad). In 
contrast to cisplatin-sensitive A2780 cells that show an efficient reduction of cell 
viability by Ad in the presence of cisplatin, cisplatin-resistant A2780/cp70 cells show 
diminishing Ad-mediated reduction of cell viability with escalating doses of cisplatin. 
Histone deacetylase (HDAC)-2 and to a lesser extent HDAC1 were up-regulated in 
cisplatin-resistant but not cisplatin-sensitive cells. Cisplatin-resistant cells treated 
with a pan-HDAC inhibitor trichostatin A (TsA) significantly enhanced Ad-mediated 
reduction of cell viability in the presence of cisplatin. Cells treated with TsA alone 
did not reduce cell viability suggesting these findings are Ad-dependent. Thus, we 
identify HDAC inhibition as a potential means to sensitise cisplatin-resistant ovarian 
cancer cells to virotherapies, an observation that may offer improved outcomes for 
patients with late stage, chemotherapy-resistant ovarian cancer. 
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INTRODUCTION
Worldwide, nearly 239,000 women were estimated 
to have been diagnosed with ovarian cancer and around 
65,600 new cases diagnosed in Europe in 2012 [1]. Patients 
commonly present at an advanced, often incurable stage, 
because of the late onset of symptoms. Although around 
80% of patients’ tumours respond initially to cytotoxic 
chemotherapy (usually up to two years), nearly all patients 
ultimately develop chemo-resistance and relapse [2]. Early 
observations of reduced tumour growth in response to 
vaccination prompted efforts to develop treatments based 
on biologics such as Ads [3]. Since then, OAds have 
been widely developed as therapies for cancer treatment 
[4]. There are 57 human Ad serotypes but those based on 
the species C Ad5 have been most widely evaluated for 
virotherapy applications. Ad5 can be readily manipulated 
by genetic or chemical means and amplified to high titers. 
However, several challenges limit the efficacy of Ad5 
clinically. Infection is dependent on cell entry via the 
native receptor, coxsackie and adenovirus receptor (CAR) 
[5]. CAR expression is frequently down-regulated as a 
function of tumour progression [6–8]. Therefore, efforts 
to target alternative receptors are under investigation 
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[9–11]. Ad5 is an endemic virus causing upper respiratory 
tract infections with up to 90% of the population having 
developed neutralising antibodies (nAbs) against Ad5 
[12, 13]. Consequently, pre-existing nAbs results in rapid, 
efficient elimination of Ad5 vectors upon in vivo systemic 
delivery [14, 15]. Ascites, an accumulation of fluid within 
the patient’s abdomen, represents a hallmark feature of 
ovarian cancer and contains nAbs as well as multiple 
cell types influencing the tumour microenvironment and 
response to chemotherapy [16, 17]. 
Clinical studies of OAds have been met with 
mixed success [18]. Onyx-015 and H101 (Oncorine) 
used in combination with chemotherapy agents in head 
and neck cancer showed little cell killing activity in 
vivo [19–23]. Imlygic (talimogene laherparepvec or 
T-Vec) developed for malignant melanoma [24] showed 
varying patient response at Phase III trial [25]. Efforts 
to develop more efficacious cancer immunotherapies by 
combining oncolytic virotherapy with chemotherapy, 
immune checkpoint modulators and epigenetic 
modifiers is attracting renewed interest [26–28]. 
Almost without exception, cancer cells display 
epigenetic (histone) aberrations that are linked to the 
development and progression of cancer [18, 29] and 
chemo-resistance [30]. HDAC inhibitors (HDACis) 
block histone deacetylation, promote cancer cell death 
and an immunogenic response [31]. These include 
vorinostat, romidepsin (FR901228, depsipeptide) 
and belinostat which have gained approval for 
haematological and solid malignancies [18]. 
It is well accepted that in addition to disturbances 
of histone acetyltransferase (HAT) and histone 
deacetyltransferase (HDAC) activity in tumour 
development, both enzymes are able to target non-histone 
targets such as viruses and proteins involved in cellular 
proliferation, migration, apoptosis and DNA repair [32].
The lack of efficacy of OAds in clinical trials prompted 
us to evaluate in this study whether potential differences 
in histone status between chemo-sensitive and-resistant 
ovarian cancer cells affect OAd efficacy. We hypothesised 
that Ad infection and replication hence efficacy might be 
altered with differences in histone regulation between 
these cell types. In the present in vitro study, we developed 
a control Ad (replication-deficient), replication-competent 
Ad5 wild-type (Ad5WT) and conditionally-replicating 
dl24 (∆24) rendered oncolytic by deletion of 24 base-pairs 
(amino acids 120-127) in the adenoviral E1A region [33]. 
We compared the efficacy of Ads in cisplatin-sensitive 
and matched -resistant ovarian cancer cells. Our findings 
outline a novel potential role for histone deacetylation 
inhibition in improving OAd-mediated reduction of 
cell viability of platinum-resistant ovarian cancer cells. 
HDACis may have important clinical implications for 
future combination trials in end-stage ovarian cancer 
patients. 
RESULTS 
Characterisation of the CAR receptor shows 
heterogeneity between patient EOC cells and 
similar expression in ovarian cancer cell lines
The native Ad5 receptor CAR is required for Ad 
infection [5]. In order to characterise the efficacy of our 
panel of Ads for this study, we sought to first determine 
the expression levels of CAR on primary epithelial ovarian 
cancer (EOC) cells cultured from clinical ascites [11] 
(data not shown). The composition of cells derived from 
metastatic sites of ovarian cancer patients in ascites varies 
widely and comprises tumour, mesothelial, fibroblast, 
immune and red blood cells. We selected two samples 
with contrasting CAR levels to test whether significantly 
different expression levels of CAR influenced Ad efficacy 
in our chemo-resistance model. EOC003 primary tumour 
cells, donated by a patient with end-stage, chemo-resistant 
disease, showed 40% of cells in total were positive for 
CAR expression as determined by flow cytometry whilst 
EOC009 cells, derived from a patient with chemo-
sensitive disease expressed 99% CAR. A2780 cisplatin-
sensitive and A2780/cp70 cisplatin-resistant cells 
expressed approximately 30% and 36% CAR expression, 
respectively (data not shown).
dl24 efficacy is comparable to Ad5WT 
We next tested the efficacy of our panel of Ads by 
performing a dose-response experiment, infecting cells 
at a multiplicity of infection (MOI) of 0-10 in matched 
cisplatin-sensitive and cisplatin-resistant ovarian cancer 
cell lines (A2780 and A2780/cp70 respectively) and 
primary epithelial ovarian cancer (EOC) tumour cell 
cultures (Figure 1). The replication-deficient control Ad 
did not reduce cell viability in any cell type. There was 
no statistically significant difference in cell viability for 
any cell type infected with Ad5WT except in SKOV3 
cells where Ad5WT decreased cell viability (P < 0.05). 
We observed a significant decrease in cell viability for 
A2780, SKOV3 and EOC003 cells (end-stage, chemo-
resistant disease) infected with dl24 in comparison to the 
replication-deficient control Ad (P < 0.05).
Cisplatin reduces Ad efficacy in cisplatin-
resistant cells 
A major clinical limitation for the treatment of 
ovarian cancer is the rapid development of chemo-
resistance. We therefore tested the efficacy of our Ads, 
as an alternative or adjunct to cisplatin, in cisplatin-
sensitive and matched -resistant cells (Figure 2). Both 
wild-type replication-competent Ad5 (Ad5WT) and 
selectively replicating dl24 showed cytotoxic effects 
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that were similar to or better than 20 µM cisplatin, alone 
or in combination with cisplatin, in cisplatin-sensitive 
A2780 cells. In matched cisplatin-resistant A2780/cp70 
cells, both Ads were much more effective than cisplatin 
when administered as a single agent and, in contrast to the 
cisplatin dose-effect seen in the A2780 cells, efficacy was 
reduced by co-administration of increasing concentrations 
of cisplatin. 
Ad transduction is comparable in cisplatin-
sensitive and -resistant cells 
To rule out any bias in our observed differences in 
Ad-mediated reduction in cell viability between cisplatin-
sensitive and -resistant cells, we performed transduction 
experiments by infecting both cell types with dl24 at 1000, 
5000 and 10,000 virus particles (vp)/cell. We observed 
no difference in transduction activity between cisplatin-
sensitive or -resistant cells, as assessed by expression of a 
virally-encoded transgene (Supplementary Figure 1). 
HDAC2 is up-regulated in cisplatin-resistant 
cells but HDAC2 knockdown has no effect on 
cell viability
The emergence of chemo-resistance has been 
associated with epigenetic modifications [30]. We sought 
to determine whether epigenetic histone modifications 
might be responsible for the observed differences in 
Ad efficacy in cisplatin-treated A2780 and A2780/cp70 
cells. We examined the expression profiles of nuclear 
HDAC1, HDAC2 and HDAC3 by flow cytometry 
(Figure 3A). A2780/cp70 cisplatin-resistant cells showed 
a marked increase in HDAC2 expression in comparison 
to cisplatin-sensitive A2780 cells (from 74.7% to 
19.8% respectively). We therefore sought to determine 
whether knockdown of HDAC2 by siRNA reverses the 
chemo-resistant phenotype. We achieved knockdown 
of HDAC2 using siRNA 1 (Figure 3B) in A2780/cp70 
cells and quantified knockdown of 76% as measured by 
densitometry (Figure 3C). However HDAC2 knockdown 
Figure 1: Ad5WT (wild-type replication-competent) and dl24 (oncolytic) Ad show specific and dose-dependent reductions in cell viability 
in (A) ovarian cancer cell lines and (B) primary epithelial ovarian cancer (EOC) cells derived from patient ascitic fluid. No reduction of cell 
viability was observed for the control Ad (replication-deficient). A2780 (cisplatin-sensitive) and A2780/cp70 (cisplatin-resistant), SKOV3 
and primary EOC (EOC003 and EOC009) cell viability in response to Ad infection (0–10 MOI) was quantified by MTS assay at 72 h post-
infection. Cell viability was calculated as a percentage of uninfected cells (control). Data was corrected for background absorbance from 
the incubation media. Data is expressed as the mean ± SEM. Experiments were performed in triplicate.
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failed to significantly alter cell viability (Figure 3D) 
suggesting HDAC2 alone is not responsible for the 
chemo-resistant phenotype of A2780/cp70 cells. HDAC1 
and HDAC2 share 83% sequence homology and exist 
together as a co-repressor complex. Knockdown of either 
HDAC1 or HDAC2 in liver and colorectal cancer cell 
lines has little effect on cell viability and proliferation, 
whereas combined knockdown of HDAC1 and HDAC2 
increases cell death and reduces cell proliferation [34]. 
We did however observe a significant increase in cell 
viability (% of uninfected control) of A2780/cp70 
cells infected with dl24 oncolytic Ad in the absence of 
cisplatin after HDAC2 knockdown by siRNA (siRNA1). 
There was no significant increase in cell viability in the 
presence of cisplatin after HDAC2 knockdown (Figure 
3E). The reasons for this observation are not clear and 
require further investigation. 
Pan-HDAC inhibition does not influence cell 
viability in the absence of Ad
To assess a potential role for HDAC over-expression 
on resistance to cancer therapies, we compared cell 
viability of cisplatin-sensitive and -resistant cells in the 
presence and absence of the pan-HDACi, trichostatin A 
(TsA). We applied cisplatin and TsA separately and in 
combination, measuring cell viability at 72 h to mimic 
the time-point for analysing cells post-infection with 
Ad (Figure 2). Cells were exposed to varying doses of 
cisplatin (0.1–10 µM, Figure 4A) and TsA (60 nM–
0.2 µM, Figure 4B) and in combination (Figure 4C). 
A2780 cisplatin-sensitive cells were more sensitive to the 
combination cisplatin and TsA treatment, than to either 
drug alone, particularly at lower doses, whilst there was 
no meaningful impact on cytotoxicity of the combination 
in A2780/cp70 cisplatin-resistant cells (Figure 4C). 
TsA enhances Ad efficacy in cisplatin-resistant 
cells exposed to cisplatin
We next tested whether histone modification 
in cisplatin-resistant cells influences Ad-mediated 
reduction of cell viability in the presence of cisplatin. 
Cells were infected with Ad (MOI = 10) and cisplatin 
(20 µM) without TsA, or in combination with either 0.3 
µM or 0.6 µM TsA and cell viability measured at 48 h 
post-infection, time-points that allow Ad replication 
to occur (Figure 5). Cisplatin-sensitive A2780 cells 
infected with Ad5WT or dl24 resulted in ~50% cell 
viability that decreased to ~10% in combination with 
cisplatin treatment, but no further reduction in cell 
viability was achieved with TsA treatment (Figure 5A). 
Replication-deficient control Ad infection with cisplatin 
and TsA treatment alone or in combination was cytotoxic 
achieving similar levels of reduced cell viability as that 
observed with Ad5WT and dl24 oncolytic Ad infection. 
Cisplatin-resistant A2780/cp70 cells infected with 
either Ad resulted in ~60% cell viability, increasing to 
~70% cell viability as expected with a chemo-resistant 
phenotype upon cisplatin treatment (20 µM) (Figure 
5B). The development of chemo-resistance is likely due 
to multiple mechanisms including alterations in drug 
transport and increased efflux out of the cell, increased 
tolerance to drug-induced DNA damaging agents, 
altered drug target and DNA repair mechanisms [35]. 
Interestingly, treatment of Ad5WT infected, cisplatin 
treated cells with 0.3 µM TsA reduced cell viability from 
~70% to 43% cell viability), with a further reduction 
Figure 2: (A) A2780 (cisplatin-sensitive) cells show enhanced Ad-mediated reduction of cell viability with escalating dose of cisplatin, 
whereas (B) A2780/cp70 (cisplatin-resistant) cells show reduced Ad-mediated reduction in cell viability with escalating dose of cisplatin. 
Cells were infected with Ad5WT (replication-competent), dl24 (oncolytic) and control Ad (replication-deficient) at an MOI of 10 and 
treated with escalating doses of cisplatin (0–20 µM). Cell viability was measured by MTS assay at 72 h post-infection. Cell viability was 
calculated as a percentage of uninfected cells (control). Data was corrected for background absorbance from the incubation media. Data is 
expressed as the mean ± SEM. Experiments were performed in triplicate.
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in cell viability to 31% with 0.6 µM TsA. Infection of 
cisplatin treated cells with dl24 and 0.3 µM TsA treatment 
reduced cell viability from ~70% to 38%, decreasing 
further to 29% cell viability with 0.6 µM TsA treatment 
(P < 0.01). The non-replicating control Ad was not 
affected by cisplatin and TsA treatment indicating 
cisplatin-resistant cells require replicating Ad. The level 
of reduced cell viability is considered to be Ad-dependent 
as in the absence of infection of cisplatin-resistant A2780/
cp70 cells, cisplatin, TsA and combination treatments 
had no effect on cell viability (94%, 110% and 87% cell 
viability respectively). Collectively, these findings show 
that pan-HDAC inhibition by TsA sensitises cisplatin-
resistant (but not cisplatin-sensitive) cells to Ad.
TsA sensitises cisplatin-resistant cells to Ad 
We sought to determine the individual and combined 
effects of TsA and dl24 oncolytic Ad cytotoxicity at 72 
h post-infection in cisplatin-sensitive and -resistant cells 
in the absence and presence of ascitic fluid from patient 
donors (Figure 6A). TsA (0.6 µM) had no significant impact 
upon the cytotoxicity achieved with OAd (MOI = 10) 
in cisplatin-sensitive cells, either alone or in combination 
with 20 µM cisplatin. In contrast, TsA produced a 
statistically significant increase in cytotoxicity achieved 
by OAd in cisplatin-resistant cells, both alone and with 
cisplatin. These findings support the suggestion, from 
Figure 5 above, that TsA selectively sensitises cisplatin-
resistant cells to Ads but not to cisplatin. 
We have previously shown that the cytotoxic 
effects of Ad5-based vectors are inhibited by the presence 
of pre-existing nAbs in ascitic fluid. In the presence of 
2.5% ascitic fluid, levels of transduction with Ad5 were 
reduced by 98.9% [36]. To test whether the sensitising 
effect of TsA is affected by the presence of ascitic fluid, 
we performed parallel experiments to those in Figure 
6A, but in the presence of 2.5% ascitic fluid (Figure 6B). 
Ascitic fluid seemed to have no meaningful quantitative or 
qualitiative impact on cytotoxicity due to the selectively 
replicating oncolytic Ad dl24, in either cisplatin-sensitive 
or -resistant cells, with or without cisplatin. Collectively, 
Figure 3: HDAC2 expression is enhanced in A2780/cp70 (cisplatin-resistant) cells in comparison to A2780 (cisplatin-
sensitive cells) but knockdown of HDAC2 has no effect on cisplatin-resistant cell proliferation. (A) Flow cytometry data 
shows quantification of HDAC1, HDAC2 and HDAC3 expression in both cell types. (B) Representative Western Blot to show HDAC2 
protein levels after siRNA 1, 2, 3 and 4 knockdown and β-actin loading control in A2780/cp70 cisplatin-resistant cells. (C) Corresponding 
densitometry plots from (B). (D) Cell viability (% of uninfected control) of A2780/cp70 cells treated with cisplatin, negative control 
(scramble) siRNA, positive control (AbI 1) siRNA or HDAC2 (siRNA1) siRNA. (E) Cell viability (% of uninfected control) of A2780/
cp70 cells infected with dl24 oncolytic Ad in the presence and absence of cisplatin after HDAC2 knockdown by siRNA (siRNA1). 
Experiments were performed in triplicate. Data is expressed as the mean ± SEM. Statistics were performed using the Sidak`s multiple 
comparison test. P values ≤ 0.05 are considered statistically significant and calculated to determine differences between Ad infected cells 
with and without different siRNAs.
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our findings show that TsA treatment selectively sensitises 
cisplatin-resistant cells to Ad but not to cisplatin.
TsA does not alter CAR expression 
To confirm whether TsA treatment of cells affects 
the levels of CAR expression, cells were analysed by 
flow cytometry 24 hours after culture in the presence 
or absence of 0.6 µM TsA (data not shown). Cultured 
A2780 cisplatin-sensitive cells demonstrated low levels 
of CAR expression. A2780/cp70 cisplatin-resistant cells 
showed two populations of cells that were negative and 
positive (22.4%) for CAR expression. TsA treatment 
slightly increased CAR expression in the sub-population 
Figure 4: In the absence of Ad infection, A2780 (cisplatin-sensitive) cells show decreased cell viability with increasing 
doses of cisplatin, TsA and combination treatments whereas A2780/cp70 (cisplatin-resistant) cells are refractory to 
drug-induced reduction of cell viability. (A) A2780 and A2780/cp70 cells were treated with cisplatin at either 0.1 µM, 0.5 µM or 
10 µM cisplatin or (B) or TsA at 0.06 µM, 0.1 µM or 0.2 µM TsA, or (C) combinations of cisplatin and TsA. Cells were harvested at 72 h. 
Cell viability was measured by MTS assay and calculated as a percentage of untreated cells (no cisplatin or TsA). All values were corrected 
for background absorbance from the incubation media. Experiments were performed in triplicate. Data is expressed as the mean ± SEM.
Figure 5: Cisplatin and TsA treatment sensitises A2780/cp70 cisplatin-resistant cells to Ad5WT (replication-competent) 
and dl24 (oncolytic) Ad. (A) A2780 and (B) A2780/cp70 cell viability at 48 h post-infection (10 MOI) in the absence and presence of 20 
µM cisplatin, 0.3 µM and 0.6 µM TsA and combination treatments. Cell viability was calculated as a percentage of uninfected cells (no Ad). 
Data was corrected for background absorbance from the incubation media. Experiments were performed in triplicate. Data is expressed 
as the mean ± SEM. Statistics were performed using the Dunnett`s multiple comparison test. P values ≤ 0.05 are considered statistically 
significant and calculated to determine differences between Ad infected cells and Ad infected cells in the presence of cisplatin.
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of CAR negative cells, however this was not statistically 
significant.
DISCUSSION
The results of clinical trials testing OAds for targeted 
cancer applications have thus far been rather disappointing 
[4, 37–40]. In this study, we tested the ability of Ad5WT 
and dl24 oncolytic Ad to reduce cell viability in cisplatin-
sensitive and -resistant ovarian cancer cells. We show 
that both Ads reduce cell viability in cisplatin-sensitive 
cells. However, we observed significantly increased 
cell viability for cisplatin-resistant cells infected with 
Ad5WT and dl24 oncolytic Ad and escalating dose of 
cisplatin. We hypothesised that the observed reduction 
in Ad efficacy with increasing cisplatin may be due to 
chromatin modifications (HDACs) in cisplatin-resistant 
cells that affect Ad replication, although elucidating the 
mechanisms for these observations are not within the 
scope of this study. 
Previous studies consider HDAC1, –3 and –7 as 
tumour biomarkers [41] and knockdown of HDAC1, –2, 
–3 and –6 in a variety of cancer cell lines can promote 
apoptosis and cell cycle arrest while HDAC1, –2 and 
-4 are required to maintain cancer cell survival in vivo 
[42]. Indeed Jones [43], describes the use of epigenetic 
therapies as an attractive strategy for treating solid cancers 
due to the ability of HDACis to cause global alterations 
in the epigenome, however the author suggests the use 
of HDACis alone are unlikely to be efficacious unless 
combined with other modalities such as chemotherapy. 
An interesting study reported enhanced efficacy of a 
combination of TsA and 5-aza-2`-deoxycitidine (DNA-
methyltransferase inhibitor) and low-dose cisplatin 
in comparison to single drug in vitro as measured by 
decreased ovarian cancer cell line cell viability, migration 
and spheroid growth [44]. Furthermore, administration 
of cisplatin followed by TsA significantly suppressed 
tumourigenicity in a mouse xenograft model. In the 
context of virotherapy, we hypothesised that differences 
in HDAC expression in chemo-resistant cells may hinder 
the ability of Ads to utilise the host`s cellular proteins for 
efficient cell entry, replication and/or promote chemo-
resistance by preventing nuclear access of cisplatin. 
In support of this idea, we found that basal HDAC2 
expression (and to a lesser extent HDAC1) is up-regulated 
in cisplatin-resistant cells. This has also been demonstrated 
in PE01 (cisplatin-sensitive) and PE04 (cisplatin-resistant) 
ovarian cancer cells soon after cisplatin treatment (24 h), 
the authors suggesting changes in nuclear texture by 
HDAC2 are possibly a mediator of an early DNA 
damage response in sensitive tumour cells [45]. Histone 
Figure 6: TsA and cisplatin/TsA are equally efficient at sensitising cisplatin-resistant cells to Ad, an effect not observed 
in cisplatin-sensitive cells where TsA has no effect. Cell viability as measured at 72 h post-infection for each Ad infected cell 
(Ad5WT or dl24 at an MOI of 10) in the absence and presence of 20 µM cisplatin, 0.6 µM TsA and combination treatments was calculated 
as a percentage of uninfected cells. (A) Experiments performed without clinical ascites fluid in the culture media and (B) in the presence of 
clinical ascites fluid. Data was corrected for background absorbance from the incubation media. Experiments were performed in triplicate. 
Data is expressed as the mean ± SEM from 3 independent experiments. Statistics were performed using the Dunnett`s multiple comparison 
test. P values ≤ 0.05 are considered statistically significant and calculated to determine differences between Ad infected cells and Ad 
infected cells in the presence of cisplatin and or TsA.
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deacetylation is a form of self-defence to injury thereby 
repressing transcription, initiating chemotherapy-triggered 
DNA damage repair and promoting survival followed by 
histone acetylation to produce open chromatin for DNA 
accessibility downstream of the injury sites. In the present 
study, knockdown of HDAC2 failed to significantly 
reduce cell viability of A2780/cp70 cisplatin-resistant 
cells. Previous studies have shown decreased cell viability 
of the parental A2780 cells after HDAC2 knockdown [46], 
whilst others have reported no reduction in cell viability 
without simultaneous knockdown of HDAC1 [47, 48]. 
Previous studies have shown that HDAC2 depletion 
by siRNA reduced the IC50 of cisplatin in PE01 cells 
suggesting loss of HDAC2 enhances the effect of cisplatin 
[45], however this observation in response to cisplatin 
may be a separate mechanism to that of cell viability in 
response to adenovirus infection as shown by the findings 
of our study. 
A limitation of our study is that other HDACs 
are likely to be involved in maintaining the phenotype 
of cisplatin-resistant cells, in particular HDAC1 which 
exhibits very close sequence homology and co-exists 
with HDAC2. In support of this, we investigated whether 
pan-HDAC inhibition (by TsA treatment) might enhance 
Ad efficacy in cisplatin-resistant cells. TsA alone did 
not affect viability of A2780 or A2780/cp70 cells. 
Cisplatin-sensitive A2780 cells infected with Ad and TsA 
demonstrated no difference in cell viability, but addition 
of cisplatin reduced cell viability, again confirming a 
cisplatin-mediated effect. Interestingly, the opposite 
effect was observed for cisplatin-resistant cells where TsA 
treatment significantly enhanced Ad-mediated reduction of 
cell viability, even in the presence of high dose cisplatin, 
suggesting that TsA sensitises cisplatin-resistant cells to 
Ad but not cisplatin. Although the addition of 600 nM 
TsA to Ad infected A2780/cp70 cisplatin-resistant cells 
decreased cell viability, 30% of cells were still remaining, 
which would not be a satisfactory outcome clinically. 
However, in this study, we only tested TsA at 300 nM and 
600 nM doses as described previously [44, 49] and showed 
a decrease in cell viability with increasing dose of TsA. It 
is possible that increasing the dose of TsA further, may 
sensitise cisplatin-resistant cells to Ad to a level sufficient 
for reaching clinical efficacy. 
Earlier studies show enhanced anti-tumour effects 
of Ad co-treated with the HDACi FR901228 in lung 
cancer cells [50] and FK228 (romidepsin) administered 
prior to Ad infection boosted infection in a melanoma 
xenograft model [51]. HDAC inhibition has been shown 
to up-regulate CAR expression in bladder cancer [52], 
although our data did not show an increase in CAR 
expression with TsA treatment suggesting TsA acts to 
enhance Ad efficacy intra-cellularly. The OAd Delta24-
RGD previously shown to lack infectivity of glioma cells 
demonstrated enhanced Ad infection through up-regulated 
αvβ3 integrin when combined with Scriptaid and LBH589 
through up-regulation of multiple cell death pathways 
[53]. A combination of Ad E1A gene therapy and SAHA 
(suberanilohydroxamic acid or Vorinostat) showed high 
therapeutic efficacy and low toxicity using in vivo ovarian 
and breast xenograft models [54].
Consistent with the potential for developing Ads for 
intra-peritoneal delivery in ovarian cancer patients, we 
repeated our experiments in the presence of ex vivo ascitic 
fluid. The accumulation of ascites represents a hallmark 
feature of ovarian cancer and contains pre-existing nAbs 
to Ad5 that may preclude the use of un-modified Ad5-
based vectors. We have previously reported that in the 
presence of 2.5% ascitic fluid (patient OAS001), levels of 
Ad transduction in EOC cells were reduced by 98.9% [36]. 
Our findings show dl24 Ad enhanced cisplatin-resistant 
reduction in cell viability with TsA treatment, even in the 
presence of ascitic fluid. 
In conclusion, this study demonstrates that Ad-
mediated reduction of cell viability is decreased with 
increasing doses of cisplatin in cisplatin-resistant 
ovarian cancer cells. Pan-HDAC inhibition by TsA 
treatment sensitises cisplatin-resistant cells to Ad, even 
in the presence of high dose cisplatin and ex vivo ascitic 
fluid. These are novel findings with potential clinical 
implications for the use of Ad vectors in chemo-resistant 
end-stage disease. 
MATERIALS AND METHODS       
Materials
Cisplatin was obtained from the Velindre Cancer 
Centre, Cardiff. Trichostatin A (TsA) was purchased 
from Sigma-Aldrich. Both reagents were suspended 
in complete incubation media supplemented with 2% 
fetal calf serum. The CellTiter 96® AQueous One Solution 
Cell Proliferation Assay [3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium)] (MTS) was purchased from Promega. HDAC 
antibodies (rabbit monoclonal) against human HDAC1, -2 
and -3 antibodies were purchased from Abcam (ab109411, 
ab32117, ab32369 respectively). HDAC2 siRNAs were 
purchased from Qiagen.
Ethics approval
Ethics permission for the collection of ascites was 
granted through a Wales Cancer Bank application for 
biomaterials, reference WCB 14/004. All patients gave 
written informed consent for the use of their samples, prior 
to collection. 
Generation of Ad vectors
Ad5WT was generated by AdZ homologous 
recombineering as previously described [55]. dl24 
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was generated from Ad5WT by AdZ homologous 
recombineering and rendered conditionally replicative 
(oncolytic) by deletion of 24 base pairs in the E1A region 
involved in binding Rb protein as previously described 
[33]. Hence dl24 is unable to induce S phase for Ad 
replication, restricting replication to actively dividing cells 
such as in the tumour microenvironment. All Ads were 
diluted in complete incubation media supplemented with 
2% fetal calf serum.
Primary epithelial ovarian cancer (EOC) cells 
Ascites samples were collected from patients with 
ovarian cancer at the Velindre Cancer Centre, Cardiff, UK 
and anonymously coded (EOC003 and EOC009). Ascites 
was stored at 4° C immediately after collection and 
processed within 24 h. Approximately 400 mL of ascites 
was centrifuged at 1000 rpm for 5 min to separate primary 
EOC cells from the fluid. The supernatant was stored at 
–70° C for subsequent use with autologous tumour cells. 
Red blood cell lysis buffer (Sigma Aldrich, UK) was added 
to the pellet according to the manufacturer`s instructions, 
where appropriate. Tumour cell pellets were frozen in 10% 
DMSO and 90% autologous supernatant (passage 0). A 
further 100 mL of ascites was used to generate primary 
EOC cultures, by separating into 20 mL aliquots and 
adding to 20 mL of complete (RPMI 1640) medium, 
supplemented with 10% (v/v) fetal calf serum (FCS), 
200 µM glutamine, 100 U/mL penicillin, 100 µg/mL 
streptomycin and 10% (v/v) autologous ascitic fluid 
supernatant. Cells were maintained at 37° C and 5% CO2. 
The resulting primary cultures were passaged when cells 
had reached confluence. All reagents were purchased from 
Gibco or Thermo Scientific (Paisley, UK). 
SKOV3, A2780 and A2780/cp70 cell lines
SKOV3 cells (human ovarian adenocarcinoma 
derived from ascites) were originally obtained from 
the American Type Culture Collection (ATCC). A2780 
parental (cisplatin-sensitive) human ovarian carcinoma 
and A2780/cp70 (cisplatin-resistant) human ovarian 
carcinoma cells were a kind gift from Dr Alwyn Dart, 
Cardiff University. Cells were cultured as described above 
and passed a mycoplasma test in November 2016. 
Coxsackie adenovirus receptor (CAR) expression 
EOC, SKOV3, A2780 and A2780/cp70 cells were 
seeded at a density of 1.5 × 105 cells per well in a 96-well 
plate. Cells were washed in 200 µl of wash buffer (PBS/1% 
BSA) and incubated with 100 µl of wash buffer containing 
1:500 of mouse anti-human monoclonal antibody against 
CAR (RmcB, Millipore, Watford, UK) or mouse IgG 
control antibody (Santa Cruz Biotechnology, Heidelberg, 
Germany) for 1 hour on ice. Cells were washed three times 
and incubated with a 1:500 dilution of goat anti-mouse 
Alexa Fluor 647 antibody (Invitrogen, UK) for 30 min on 
ice. Cells were fixed in 4% paraformaldehyde for 20 min 
at 4° C. 2 × 104 gated events were acquired in channel 
FL-4 on a BD Accuri C6 (BD Biosciences, USA) flow 
cytometer and data analysed in BD Accuri C6 software 
version 1.0.264.21 (Becton Dickinson, USA). hCAR 
expression was analysed by flow cytometry relative to IgG 
isotype expression.
Ad infection and cell viability
Cells were seeded in 96-well plates at a density of 
2 × 104 cells/well in 100 µl of RPMI media supplemented 
with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin. Cells were 
incubated in humidified boxes at 5% CO2, 37° C. After 
24 h, cells were infected with Ad at an MOI of 0–10 
(calculated as the ratio between the number of Ad particles 
and number of cells) and cultured as described above. Cell 
viability (% relative to uninfected cells) was measured by 
MTS assay. In brief, 20 µl of CellTiter 96® AQueous One 
Solution Cell Proliferation Assay reagent was added 
to 100 µl of culture medium, followed by incubation 
at 5% CO2, 37°
 C for 2 h. Plates were read at 490 nM 
using a multimode plate reader (FLUOstar Omega, BMG 
Labtech, Aylesbury, UK). Cell viability for cells infected 
with Ad was calculated as a percentage of uninfected 
cells (control). All values were corrected for background 
absorbance from the incubation media. All experiments 
were performed in triplicate. Data are expressed as the 
mean ± SEM.
Ad infection in combination with cisplatin dose 
escalation and cell viability 
Cells were seeded in 96-well plates at a density 
of 2 × 104 cells/well in RPMI media supplemented 
with 10% fetal calf serum, 2 mM L-glutamine, 100 U/
ml penicillin and 100 µg/ml streptomycin. Cells were 
incubated in humidified chambers at 37° C, 5% CO2. 
After 24 h, cells were infected with Ad at 100 MOI in 
RPMI media supplemented with 2% fetal calf serum, 2 
mM L-glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin. At 2 h post-infection, cisplatin was added 
to cells at doses of 0.01, 1, 10 and 20 µM. Cisplatin only 
cells were treated with 20 µM cisplatin. Cell viability 
was measured at 72 h post-infection by MTS assay as 
described above. Cell viability for each Ad infected cell 
in the absence and presence of cisplatin was calculated 
as a percentage of uninfected cells (no Ad or cisplatin). 
Data was corrected for background absorbance from 
the incubation media. Experiments were performed in 
triplicate. Data are expressed as the mean ± SEM from 3 
independent experiments. Statistics were performed using 
the Dunnett`s multiple comparison test. P values ≤ 0.05 
are considered statistically significant and calculated to 
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determine differences between adenovirus infected cells 
and adenovirus infected cells in the presence of cisplatin.
Ad transduction
Assays were performed as previously described 
[13]. In brief, cells were seeded at a density of 2 × 104 
cells/well in a 96-well plate. After 24 hours, cells were 
infected with a luciferase expressing dl24 Ad at doses 
of 1000, 5000 and 10 000 virus particles (vp) per cell 
in a total volume of 100 µl of serum-free medium and 
incubated at 5% CO2, 37°
 C for 3 hours. The medium was 
removed and replaced with 200 μl of complete medium 
(RPMI 1640 medium supplemented with 10% (v/v) fetal 
calf serum, 100 U/mL penicillin, 100 µg/mL streptomycin) 
and cultured for an additional 45 hours. Cells were lysed 
in 1 × Cell Culture Lysis Buffer (Promega, UK) and 
frozen at –70° C. The cells were thawed and 20 µl of cells 
mixed with 100 µl of luciferase assay reagent in a white 
96-well plate. Luciferase activity in relative light units 
(RLU) was measured immediately using a multimode 
plate reader (FLUOstar Omega, BMG Labtech, Aylesbury, 
UK). Samples were normalised for total protein content, 
as measured by bicinchoninic acid (BCA) assay in 
RLU/mg protein. 2 × 104 gated events were acquired in 
channel FL-1 on a BD Accuri C6 using the plate reader as 
described above.
Intracellular HDAC expression 
A2780 and A2780cp/70 cells were seeded at 
a density of 1 × 105 cells per well, fixed with 4% 
paraformaldehyde, permeabilised with 0.1% Triton-X100 
in PBS and blocked with 10% normal goat serum. Cells 
were incubated with rabbit anti-HDAC1, anti-HDAC2 
and anti-HDAC3 antibodies (1:50) (Abcam, Cambridge, 
UK) and detected with Alexa Fluor 488 goat anti-rabbit 
secondary antibody (1:2000) (Invitrogen, Paisley, UK). 
2 × 104 gated events were acquired in channel FL-1 on a 
BD Accuri C6 using the plate reader as described above. 
HDAC expression was determined relative to the IgG 
isotype expression.
HDAC2 siRNA transfection 
A2780/cp70 (cisplatin-resistant cells) were seeded 
at 10 × 104 cells per well in a 96-well plate in complete 
incubation media in the absence of antibiotics. 24 h after 
seeding, cells were transfected with 6 pmol HDAC2 
siRNAs, All Stars negative control (scrambled) or AbI 1 
5 (positive control) (Qiagen) and 0.3 µl Lipofectamine 
reagent per well in OptiMEM media (in triplicate). 
Transfection control wells contained nuclease-free water 
and OptiMEM media only. Cells were incubated in a 
humidified box at 37° C, 5% CO2. For cisplatin wells, cells 
were incubated for 2 h then dosed with 20 µM cisplatin. 
Cell viability was measured at 48 h by MTS assay and 
calculated as a percentage of non-transfected cells. All 
values were corrected for background absorbance from 
the incubation media. Experiments were performed in 
triplicate. Data is expressed as the mean ± SEM.
Western blotting
Cells were lysed in 1% SDS lysis buffer (50 mM 
Tris HCl, pH 6.8, 10% glycerol, 1% SDS). Each triplicate 
wells were pooled. 10 µl of each sample were used for a 
BCA assay. Samples were freeze thawed and diluted as 
appropriate with water to 10 µg. Samples were centrifuged 
at full speed and the same volume of 2 X Laemmli 
buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 
0.004% bromophenol blue, 0.125M Tris HCl) added to 
each sample. Samples were boiled at 95° C for 10 mins. 
Samples were loaded onto a 10% pre-cast Bis-Tris SDS-
PAGE gel and electrophoresed at 200 V for 1 h. Gels 
were transferred at 20 V for 1 h (semi-dry transfer) to a 
nitrocellulose membrane. Membranes were blocked in 
1 X TBST, 2% BSA at 37° C, room temperature (RT) 1 
h. The siRNA membrane was incubated with rabbit anti-
HDAC2 antibody (ab32117) (1:2000) in 1 X TBST, 2% 
BSA and the positive control siRNA AbI 1 membrane 
was incubated in mouse anti-ABI antibody (1:200) in 1 
X TBST, 2% BSA overnight at 4° C. Membranes were 
washed 3 × 10 min in 1 X TBST. Anti-rabbit HRP and 
anti-mouse HRP (1:2000) in 1 X TBST, 2% BSA was 
added to each membrane respectively and incubated 
at RT for 1 h. Membranes were washed 3 × 10 min in 
1 X TBST. Membranes were incubated with West Pico 
chemiluminescent reagent and immediately imaged. For 
actin loading control, membranes were stripped (Restore 
Western Blot Stripping buffer) for 15 min at RT and 
washed with 1 X TBST and incubated with rabbit anti-
actin antibody (1:2000) in 1 X TBST, 2% BSA for 1 h at 
RT. Membranes were washed 3 × 10 min in 1X TBST. 
Membranes were incubated with anti-rabbit HRP antibody 
(1:2000) in 1X TBST, 2% BSA for 1 h at RT. Membranes 
were washed 3 × in 1 X TBST and incubated with West 
Pico. Membranes were imaged immediately.
Cisplatin and TsA dose response in the absence 
of Ad and cell viability
A2780 and A2780/cp70 cells were seeded at 2 × 104 
cells/well in RPMI media supplemented with 10% fetal 
calf serum, 2 mM L-glutamine, 100 U/ml penicillin and 
100 µg/ml streptomycin in 96-well plates incubated in 
humidified boxes at 37° C, 5% CO2. Cells were treated 
with cisplatin at either 100, 50, 10 or 1 µM and TsA 
at either 2 µM, 1 µM or 600 nM as described above. 
Combinations of each dose of cisplatin and TsA were 
also tested. Cells were harvested at 72 h. Cell viability 
was measured by MTS assay (as described above) and 
calculated as a percentage of untreated cells (no cisplatin 
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or TsA). All values were corrected for background 
absorbance from the incubation media. Experiments were 
performed in triplicate. Data are expressed as the mean ± 
SEM. 
Efficacy of Ad in combination with cisplatin and 
TsA co-treatment
A2780 and A2780cp/70 cells were seeded at 2 × 
104 cells/well in complete media containing 10% fetal 
calf serum, 2 mM L-glutamine, 100 U/ml penicillin and 
100 µg/ml streptomycin in 96-well plates incubated in 
humidified boxes at 37° C, 5% CO2. After 24 h, cells were 
infected with Ad5WT, dl24 or control Ad at 100 MOI 
in RPMI media supplemented with 2% fetal calf serum, 
2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin. At 2 h post-infection, 20 µM cisplatin and 
either 300 nM or 600 nM TsA [36] was added to cells. 
Cisplatin only wells were treated with 20 µM cisplatin. 
TsA only cells were treated with 600 nM TsA. Cells were 
harvested at 24 h, 48 h, 72 h and 144 h. Cell viability 
was measured by MTS assay as described above. Cell 
viability for each Ad infected cell in the absence and 
presence of cisplatin and or TsA was calculated as a 
percentage of uninfected cells (no Ad). All values were 
corrected for background absorbance from the incubation 
media. Experiments were performed in triplicate. Data 
are expressed as the mean ± SEM. P values ≤ 0.05 were 
considered statistically significant and calculated to 
determine differences in cell viability between Ad infected 
cells in the presence of cisplatin and adenovirus infected 
cells in the presence of cisplatin and TsA.
Efficacy of Ad in combination with cisplatin and 
TsA co-treatment in the presence of clinical ex 
vivo ovarian cancer ascitic fluid
A2780 and A2780cp/70 cells were seeded in 
96-well plates at a density of 2 × 104 cells / well in 
RPMI media supplemented with 10% fetal calf serum, 
2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin. Cells were incubated in humidified boxes 
at 37° C, 5% CO2. After 24 h, cells were infected with 
Ad5WT or dl24 at 100 MOI in RPMI media supplemented 
with 2% fetal calf serum, 2 mM L-glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin. At 2 h post-
infection, 20 µM cisplatin and/or 600 nM of TsA and 2.5% 
ascitic fluid containing highly neutralising antibodies to 
Ad5 (patient OAS001) [36] was added to cells. Cisplatin 
only wells were treated with 20 µM cisplatin. TsA only 
cells were treated with 600 nM TsA. Cells were harvested 
at 24 h, 48 h and 72 h. Cell viability was measured by 
MTS assay as described above. Cell viability for each 
adenovirus infected cell in the absence and presence 
of cisplatin and or TsA was calculated as a percentage 
of uninfected cells (no Ad). All values were corrected 
for background absorbance from the incubation media. 
Experiments were performed in triplicate. Data are 
expressed as the mean ± SEM. The broken line indicates 
the percentage of cell viability of non-infected cells 
incubated with cisplatin and TsA only.
TsA treatment and CAR expression 
Cells were seeded at a density of 2 × 104 cells per 
well (day 0). After 24 h (day 1), cells were treated with 
TsA (600 nM). Cells were maintained at 37° C, 5% CO2 
in a humidified chamber. At 24 h post-treatment, cells 
were stained for CAR expression. Primary antibodies 
were mouse IgG isotype control antibody (Santa Cruz 
Biotechnology, Heidelberg, Germany) (1:200) or mouse 
anti-hCAR antibody (RmcB, Millipore, Watford, UK) 
(1:500) for 1 h at 4° C followed by detection with anti-
mouse Alexa Fluor 647 (Invitrogen, UK) (1:500) for 45 
min at 4° C. Cells were fixed in 4% paraformaldehyde 
for 20 min at 4° C. CAR expression was analysed by flow 
cytometry relative to IgG isotype expression using the BD 
Accuri C6 as described above.
Statistical analyses
Data are presented as experiments performed 
in triplicate. Analysis of variance (ANOVA) and the 
Dunnett’s or Sidak`s multiple comparisons post hoc 
test was performed when three or more groups of data 
were analysed. All analyses and graphs were created in 
GraphPad Prism version 6.03 (GraphPad Software Inc., 
La Jolla, CA, USA).
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